EGFR-ERBB2 is considered as an anti-cancer target in a variety of cancers, such as breast cancer, malignant peripheral nerve sheath tumors, suggesting that the changes in GSL metabolism pathway activity in fibroblasts may affect cells of other types through these specific ligand-receptor interaction (38). Here, ERBB2 is linked to breast carcinoma.